AbbVie @abbvie · 03 Sep 2026
New topline results are available from our Phase 3 study in patients with relapsed/refractory #MultipleMyeloma (RRMM), and we look forward to sharing the full data at this year’s @Myeloma_Society Annual Meeting. Read more: https://t.co/Qx1rjb26cS #IMS26 https://t.co/vZsf2ycn9n
1 293Views
1Likes
1Reposts
3Replies
1Quotes
0Bookmarks
Is that a lot?
1.41×vs this author's median917 views is typical
50Percentile for this authorof 8 recent posts
0.50×vs 10K–100K median2 578 views is typical
1.63%Reachviews ÷ followers
0.46%Engagement rateof viewers reacted